AVITA Medical, Inc. (RCEL)
16.20
-1.10
(-6.36%)
USD |
NASDAQ |
Nov 12, 16:00
16.16
-0.04
(-0.25%)
After-Hours: 07:52
AVITA Medical Enterprise Value : 538.23M for Nov. 12, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 12, 2026 | 538.23M |
| November 11, 2026 | 572.29M |
| November 10, 2026 | 583.12M |
| November 09, 2026 | 566.71M |
| November 06, 2026 | 550.30M |
| November 05, 2026 | 522.13M |
| November 04, 2026 | 541.94M |
| November 03, 2026 | 511.29M |
| November 02, 2026 | 513.77M |
| October 30, 2026 | 521.20M |
| October 29, 2026 | 554.02M |
| October 28, 2026 | 547.52M |
| October 27, 2026 | 534.51M |
| October 26, 2026 | 506.64M |
| October 23, 2026 | 516.86M |
| October 22, 2026 | 514.08M |
| October 21, 2026 | 510.05M |
| October 20, 2026 | 463.92M |
| October 19, 2026 | 443.48M |
| October 16, 2026 | 440.38M |
| October 15, 2026 | 451.84M |
| October 14, 2026 | 442.24M |
| October 13, 2026 | 450.29M |
| October 12, 2026 | 450.60M |
| October 09, 2026 | 445.65M |
| Date | Value |
|---|---|
| October 08, 2026 | 449.36M |
| October 07, 2026 | 440.69M |
| October 06, 2026 | 438.84M |
| October 05, 2026 | 446.89M |
| October 02, 2026 | 430.48M |
| October 01, 2026 | 408.49M |
| September 30, 2026 | 399.82M |
| September 29, 2026 | 407.23M |
| September 28, 2026 | 398.26M |
| September 25, 2026 | 403.52M |
| September 24, 2026 | 395.48M |
| September 23, 2026 | 375.99M |
| September 22, 2026 | 392.69M |
| September 21, 2026 | 372.59M |
| September 18, 2026 | 378.16M |
| September 17, 2026 | 384.34M |
| September 16, 2026 | 360.53M |
| September 15, 2026 | 353.11M |
| September 14, 2026 | 352.49M |
| September 11, 2026 | 342.90M |
| September 10, 2026 | 342.28M |
| September 09, 2026 | 351.56M |
| September 08, 2026 | 359.29M |
| September 04, 2026 | 383.73M |
| September 03, 2026 | 375.69M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Iovance Biotherapeutics, Inc. | 3.198B |
| Halozyme Therapeutics, Inc. | 13.65B |
| Agenus, Inc. | 494.26M |
| Amgen, Inc. | 293.45B |
| Fate Therapeutics, Inc. | 98.22M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -6.222M |
| Revenue (Quarterly) | 26.11M |
| Total Expenses (Quarterly) | 32.34M |
| EPS Diluted (Quarterly) | -0.2016 |
| Gross Profit Margin (Quarterly) | 84.02% |
| Profit Margin (Quarterly) | -23.83% |
| Earnings Yield | -7.29% |
| Normalized Earnings Yield | -7.862 |